Latest news with #analystreports
Yahoo
a day ago
- Business
- Yahoo
This TSX stock has analysts stretching their price targets, with one analyst upping it nearly 80%
It was another earnings smorgasbord with plenty of analyst reports to parse through. In the search for nuggets, FP highlights five , including and Equinox Gold Corp., while BMO Capital Markets' chief investment strategist looks past the with a bullish outlook for the Toronto market. Also look for analysts' take on S&P/TSX composite superstar Stock of the week: Gildan Activewear Inc. Gildan Activewear Inc. (TSX:GIL) sewed up a nice week of gains, rising almost 10 per cent, as analysts gave the nod to the Montreal-based clothing manufacturer's move to purchase North Carolina-based Hanesbrands Inc. Vershal Shreedhar, an analyst at National Bank of Canada, said the deal makes strategic sense because it will help Gildan diversify its markets, but cautioned it also entails risks as Hanesbrands' prospects have been shrinking over the years. Nonetheless, he maintained his price target of $80 for Gildan. The stock is currently trading in the high $70s. 'We believe that Gildan is a solid company; it has many drivers for EPS growth, including revenue growth, improving costs, and share repurchases,' Shreedhar said in a note. TD Cowen analyst Brian Morrison also likes the deal, saying in a note that the purchase 'should position Gildan as a global leader in apparel basics.' He has a buy recommendation on the stock and a price target of $82.63. Of the analysts covering Gildan, 92 per cent rated the stock a buy, with Morningstar Inc. analyst David Swartz upgrading his price target to the highest amongst the group — to $128.43 from $72 — according to Bloomberg. Keeping score Don't let the trade trash talk get you down Brian Belski is still bullish on Canadian stocks. 'Despite persistent trade rhetoric, we remain steadfast that Canada is well-positioned fundamentally and that investors should remain focused on the broader fundamental normalization process that is well under way in our view,' the chief investment strategist at BMO Capital Markets said in a note on Aug. 12. He pointed to normalizing Canadian earnings, including positive revisions, stabilizing profitability metrics, growth expectations that are likely to hit double digits by year-end and earnings per share estimates that are trending higher. He has a target for the S&P/TSX composite index of 28,500 for the end of the year. Gold shines bright among TSX gainers Gold companies and other precious metals miners have consistently ranked in the Top 10 S&P/TSX composite weekly gainers since at least late June. That's not a surprise given that the price of gold is up 27 per cent year to date, though it's lately been bouncing around the US$3,300 to US$3,400 an ounce range. Earnings from these companies have been pouring in over the past few weeks, so we thought we would take a quick look at price targets analysts have issued for some names in the sector. Barrick Gold Corp. (TSX:ABX): TD Cowen has a $41.35 price target on Barrick, which is currently trading in the low $30s, up just under three per cent from the end of last week. Stephen Green, an analyst at Toronto-Dominion Bank, cited an increase of five cents per share in the dividend and ongoing share buybacks as positives for the stock. Equinox Gold Corp. (TSX:EQX): Michael Siperco at RBC Dominion Securities Inc. has a 'positive' view of Equinox and a price target of $11, with the stock currently trading around $11.20. He likes Equinox after a California mining project was approved for a fast-track permitting process, with two other projects ramping up this year. Kevin O'Halloran, an analyst at BMO Capital Markets, has a $13 price target on Equinox. Galiano Gold Inc. (TSX:GAU): Raj Ray, an analyst at BMO Capital Markets, increased his price target for Galiano to $2.50 from $2. 'We will look for two to three quarters of consistent results to get more constructive,' he said in a note. Galiano is trading around $2.70 and is up 27 per cent since releasing its earnings earlier this week. Artemis Gold Inc. (TSXV:ARTG): 'We expect a positive reaction from (Artemis) shares following a solid Q2,' analysts Wayne Lam and Kulvir Gill at TD Cowen said in a note this week, adding that the company's results beat consensus on higher gold sales and a higher 'realized price.' The pair maintained their price target of $31 after hiking it to that level in July from $24. The stock has posted a strong year to date, climbing about 76 per cent. It's currently trading around $28.50. Aya Gold and Silver Inc. (TSX:AYA) CIBC Capital Markets analyst Cosmos Chiu is expecting a lot from Aya, given he has a price target of $22 on the shares, which are currently trading at a bit more than $12. Second-quarter earnings met expectations and Chiu is looking for a strong second half after company executives maintained guidance on gold production of five to 5.3 million ounces and cash costs. Reaching for the constellations Don't let Constellation Software Inc.'s (TSX:CSU) current share price of $4,308 scare you. Analysts David Kwan and Mahmoud Halloum at TD Cowen think the recent weakness in the shares — they dropped about 11 per cent after reporting earnings on July 8 — provide an opening for investors, calling the stock a 'great buying opportunity' and describing it as a 'proven high-quality defensive name.' The pair hiked their price target to $5,700 from $5,600, providing a pecking order in the software sphere, with the Toronto-based company first, Inc. (TSX:TOI) second and Lumine Group Inc. (TSX: LMN) third. This TSX juggernaut has another 25% upside, CIBC analyst says Hurricane season is heating up and these Canadian oil stocks are poised to benefit • Email: gmvsuhanic@
Globe and Mail
09-07-2025
- Business
- Globe and Mail
The Zacks Analyst Blog Highlights T-Mobile US, AstraZeneca and Comcast
For Immediate Release Chicago, IL – July 9, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: T-Mobile US, Inc. TMUS, AstraZeneca PLC AZN and Comcast Corp. CMCSA. Here are highlights from Tuesday's Analyst Blog: Top Analyst Reports for T-Mobil, AstraZeneca and Comcast The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., AstraZeneca PLC and Comcast Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Mixed at Start of Prime Day, Awaiting Trade Deals Today's Featured Research Reports T-Mobile's shares have outperformed the Zacks Wireless National industry over the past year (+34.5% vs. +30.7%). The company is benefiting from industry-leading postpaid customer growth with a record-low churn rate. Its acquisition strategy has significantly strengthened its position in the wireless industry over the past few years. TMUS' 2.5 GHz 5G spectrum delivers superfast speeds and extensive coverage with signals that go through walls and trees. This boosts its competitive edge against companies that provide 5G networks controlled by the mmWave spectrum. However, owing to the stock's premium valuation, we believe investors should remain cautious as macroeconomic factors, market saturation, or economic downturns can significantly impact overvalued stocks like TMUS. Fierce competition is straining profitability. To lure customers from competitors, T-Mobile has launched several low-priced service plans for consumers. This has put pressure on profits. (You can read the full research report on T-Mobile here >>>) Shares of AstraZeneca have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+7.7% vs. -2%). The company's key drugs like Lynparza, Tagrisso, Imfinzi and Fasenra should keep driving revenues. Its pipeline is strong, with pivotal late- and mid-stage pipeline data readouts lined up. AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline. AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology sales and slowing sales of rare disease drugs are expected to hurt the top line in 2025. Estimates have declined slightly ahead of the Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters. (You can read the full research report on AstraZeneca here >>>) Comcast's shares have underperformed the Zacks Cable Television industry over the year-to-date period (-3.1% vs. +4.2%). The company has been persistently suffering from video-subscriber attrition due to cord-cutting. Broadband prospects are suffering from increased competition from fixed wireless and fiber businesses. Theme Parks revenues declined due to lower revenues at domestic theme parks, driven by lower guest attendance, including the impact of the Hollywood wildfires. A leveraged balance sheet is a major concern for Comcast. Nevertheless, steady growth in Content & Experiences revenues driven by steady performances by Studios and Media segments is positive. Its streaming service, Peacock, has been a key catalyst in driving broadband sales. Decreasing programming & production costs bode well for CMCSA's profitability. Strong free cash flow generation ability is noteworthy. (You can read the full research report on Comcast here >>>) Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report T-Mobile US, Inc. (TMUS): Free Stock Analysis Report
